Akero Therapeutics, Inc. AKRO
We take great care to ensure that the data presented and summarized in this overview for Akero Therapeutics, Inc. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding AKRO
View all-
Wellington Management Group LLP Boston, MA7.9MShares$232 Million0.04% of portfolio
-
Janus Henderson Group PLC London, X07.08MShares$208 Million0.11% of portfolio
-
Rtw Investments, LP New York, NY5.92MShares$174 Million2.71% of portfolio
-
Black Rock Inc. New York, NY5.59MShares$164 Million0.0% of portfolio
-
General Atlantic LLC New York, NY5.23MShares$154 Million4.29% of portfolio
-
Price T Rowe Associates Inc Baltimore, MD3.81MShares$112 Million0.01% of portfolio
-
Vanguard Group Inc Valley Forge, PA3.68MShares$108 Million0.0% of portfolio
-
Alkeon Capital Management LLC New York, NY3.33MShares$97.6 Million0.16% of portfolio
-
State Street Corp Boston, MA2.5MShares$73.4 Million0.0% of portfolio
-
Alliancebernstein L.P. New York, NY2.02MShares$59.2 Million0.02% of portfolio
Latest Institutional Activity in AKRO
Top Purchases
Top Sells
About AKRO
Akero Therapeutics, Inc., a cardio-metabolic nonalcoholic steatohepatitis (NASH) company, engages in the development of medicines designed to restore metabolic balance and improve overall health. The company's lead product candidate is efruxifermin (EFX), an analog of fibroblast growth factor 21, which protects against cellular stress and regulates metabolism of lipids, carbohydrates, and proteins throughout the body. It also conducts a Phase 2a clinical trial, the BALANCED study, to evaluate EFX in the treatment of biopsy-confirmed NASH patients. The company was formerly known as Pippin Pharmaceuticals, Inc. and changed its name to Akero Therapeutics, Inc. in May 2018. Akero Therapeutics, Inc. was incorporated in 2017 and is headquartered in South San Francisco, California.
Insider Transactions at AKRO
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Dec 17
2024
|
Timothy Rolph Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
3,800
-2.09%
|
$117,800
$31.1 P/Share
|
|
Dec 17
2024
|
Timothy Rolph Chief Scientific Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
3,800
+2.04%
|
$72,200
$19.87 P/Share
|
|
Dec 16
2024
|
Jonathan Young Chief Operating Officer |
BUY
Grant, award, or other acquisition
|
Direct |
24,300
+9.63%
|
-
|
|
Dec 16
2024
|
Catriona Yale Chief Development Officer |
SELL
Open market or private sale
|
Direct |
9,074
-8.66%
|
$263,146
$29.11 P/Share
|
|
Dec 16
2024
|
Catriona Yale Chief Development Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
9,074
+7.97%
|
$190,554
$21.1 P/Share
|
|
Dec 16
2024
|
Catriona Yale Chief Development Officer |
BUY
Grant, award, or other acquisition
|
Direct |
24,300
+20.26%
|
-
|
|
Dec 16
2024
|
Patrick Lamy Senior VP, Commercial Strategy |
SELL
Open market or private sale
|
Direct |
1,000
-2.84%
|
$29,000
$29.13 P/Share
|
|
Dec 16
2024
|
Patrick Lamy Senior VP, Commercial Strategy |
BUY
Grant, award, or other acquisition
|
Direct |
17,400
+33.04%
|
-
|
|
Dec 16
2024
|
Scott A. Gangloff Chief Technology Officer |
BUY
Grant, award, or other acquisition
|
Direct |
24,300
+50.0%
|
-
|
|
Dec 16
2024
|
William Richard White Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
24,300
+27.95%
|
-
|
|
Dec 16
2024
|
Andrew Cheng President and CEO |
BUY
Grant, award, or other acquisition
|
Direct |
98,500
+12.4%
|
-
|
|
Dec 16
2024
|
Timothy Rolph Chief Scientific Officer |
BUY
Grant, award, or other acquisition
|
Direct |
20,000
+9.16%
|
-
|
|
Dec 10
2024
|
Timothy Rolph Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
4,818
-1.33%
|
$144,540
$30.91 P/Share
|
|
Dec 10
2024
|
Timothy Rolph Chief Scientific Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
2,450
+1.34%
|
$46,550
$19.87 P/Share
|
|
Dec 10
2024
|
Jonathan Young Chief Operating Officer |
SELL
Open market or private sale
|
Direct |
2,503
-1.21%
|
$75,090
$30.79 P/Share
|
|
Dec 10
2024
|
Andrew Cheng President and CEO |
SELL
Open market or private sale
|
Direct |
7,855
-1.3%
|
$235,650
$30.79 P/Share
|
|
Dec 10
2024
|
William Richard White Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
2,817
-6.85%
|
$84,510
$30.79 P/Share
|
|
Dec 10
2024
|
Catriona Yale Chief Development Officer |
SELL
Open market or private sale
|
Direct |
2,810
-3.79%
|
$84,300
$30.79 P/Share
|
|
Dec 10
2024
|
Patrick Lamy Senior VP, Commercial Strategy |
SELL
Open market or private sale
|
Direct |
925
-4.92%
|
$27,750
$30.79 P/Share
|
|
Dec 02
2024
|
Jonathan Young Chief Operating Officer |
SELL
Open market or private sale
|
Direct |
10,000
-4.62%
|
$320,000
$32.13 P/Share
|
Last 12 Months Summary
| Grant, award, or other acquisition | 238K shares |
|---|---|
| Exercise of conversion of derivative security | 948K shares |
| Open market or private sale | 914K shares |
|---|